Podcasts about SCLC

Small cell lung cancer has historically had few treatment options — but that's changing fast. In this episode, thoracic oncologist Dr. Ashish Saxena (Weill Cornell Medicine) joins host and SCLC survivor Wendy Brooks to discuss why asking about clinical trials early matters, how patient-reported outcomes are reshaping what "success" means in treatment, the newest immunotherapy and antibody drug conjugate approaches, and why speaking up about side effects helps both patients and future research. Visit lcfamerica.org to learn more. Guests:  Dr. Ashish Saxena, MD, PhD — Chief of Thoracic Medical Oncology, Weill Cornell Medicine Wendy Brooks, Voices of Hope Speakers Bureau member living with SCLC   Show Notes - https://lcfamerica.org/wp-content/uploads/2026/09/HWA-SCLC-Research-Innovation-Show-Notes.pdf   Transcript - https://lcfamerica.org/wp-content/uploads/2026/09/HWA-SCLC-Research-Innovation-Transcript.pdf  Watch Video - https://youtu.be/SYMHnFezSJI    Subscribe to Hope With Answers Living With Lung Cancer podcast for future episodes on your favorite listening platform. Apple Podcast | Spotify | Amazon Play | iHeart   Join LCFA's social media communities for support and information. Facebook | Twitter | Instagram | YouTube

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself to meet increasing global demand for affordable treatments. This initiative not only enhances their production capabilities but also aligns with the push from healthcare systems worldwide for more economical care options. The vertical integration model promises to streamline production, reduce supply chain issues, and maintain high-quality standards, reinforcing Sandoz's competitive position in the biosimilars market. Meanwhile, Amgen has achieved a noteworthy milestone with its drug Imdelltra (tarlatamab-dlle), which met its Phase 3 overall survival endpoint for extensive-stage small-cell lung cancer (SCLC) maintenance therapy. Imdelltra, a bispecific T-cell engager targeting DLL3, represents a novel approach in oncology, potentially setting a new standard of care for SCLC patients who have severely limited treatment options. The positive trial results could lead to regulatory approval, broadening access to this innovative therapy and potentially improving patient outcomes significantly. Regulatory stability is on the horizon with the FDA appointing permanent heads for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). This leadership continuity is crucial as it supports the agency's ongoing restructuring efforts aimed at enhancing efficiency and oversight. Stable leadership within these centers ensures rigorous drug evaluation processes continue, which is critical for timely approvals and has a direct impact on drug developers' strategic planning and market entry timelines. Clinical trials continue to yield varied results, showcasing the inherent uncertainties in drug development. AstraZeneca's Tozorakimab showed promise with approximately a 30% reduction in exacerbations in Phase 3 trials for chronic obstructive pulmonary disease (COPD), hinting at improved management of respiratory diseases through targeted monoclonal antibody therapies. Conversely, challenges persist as Evommune's Evo756 did not meet its Phase 2b trial expectations for atopic dermatitis, and Tyra Biosciences' Dabogratinib fell short in non-muscle invasive bladder cancer trials—highlighting the unpredictable nature of clinical research. Investment flows into biopharmaceuticals remain robust, with Encoded Therapeutics raising $275 million to advance its gene therapy program for Dravet syndrome. Similarly, Luma Group has secured $410 million for ventures focusing on ophthalmology and cellular rejuvenation technologies. Such investments reflect strong confidence in gene and cell therapies' transformative potential on patient care. On the mergers and acquisitions front, Sernova Biotherapeutics' merger with Seraxis to form Betanova Biotherapeutics exemplifies how companies are consolidating expertise to enhance R&D capabilities and expand their market reach, particularly in cell therapy solutions for diabetes management. These strategic consolidations indicate ongoing efforts to leverage synergies that could redefine therapeutic landscapes. The biopharmaceutical sector is also seeing shifts due to ongoing geopolitical tensions between the U.S. and China, pushing companies to seek investment opportunities outside China. This diversification strategy aims to mitigate geopolitical risks while continuing global innovation efforts. In obesity treatment research, partnerships like those between GemPharmaTech signal new frontiers beyond GLP-1 receptor agonists. These collaborations highlight an industry commitment to tackling global health challenges with innovative therapies that prioritize efficacy and safety. These developments collectively paint a picture of a dynamic industry marked by scientific breakthroughs, strategic investments, regulatory evolution, and significant challenges in clinical trials. As these sectors evolve, they promise exciting advancements that could profoundly redefine global healthcare paradigms. The focus remains on overcoming therapeutic barriers through sustained research efforts and innovative approaches—a testament to the industry's relentless pursuit of improving patient care outcomes worldwide.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

Small cell lung cancer (SCLC) has historically lagged behind other cancers in treatment innovation — but that's changing fast. In this Hope With Answers episode, 8-year SCLC survivor and LCFA patient host Maida Mangiameli talks with Dr. Jacob Sands, Associate Chief of Thoracic Oncology at Dana-Farber Cancer Institute, about the surge of new SCLC clinical trials, why immunotherapy has changed long-term outcomes, and what newly diagnosed patients need to know about acting quickly. Learn more at LCFAmerica.org. Guests: Dr. Jacob Sands (Dana-Farber Cancer Institute) Maida Mangiameli (LCFA Patient Host, SCLC Survivor) Resources Show Notes - https://lcfamerica.org/wp-content/uploads/2026/08/HWA-Fall-2026-SCLC-Advances-Deeper-Dive-Show-Notes.pdf  Transcript - https://lcfamerica.org/wp-content/uploads/2026/08/HWA-Fall-2026-SCLC-Deeper-Dive-Transcript.pdf Watch Video - https://youtu.be/wxLk2OqKuB4  

Featuring an interview with Prof Ticiana Leal, including the following topics: Pathophysiology and clinical signs and symptoms (0:00) Screening and/or diagnostic approaches (5:45) Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36) Key clinical trial data for amifampridine and practicalities of its administration (14:05) Building awareness among patients, caregivers and the oncology community (22:37) Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35) Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41) Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55) Current research and potential developments in the treatment of SCLC (48:32) CME information and select publications

 Voters Right Act, Chicago Tribune, Slate, NY Times On the Eve of the 2026 March on Washington, we reflect back to August 6th, 1965 the Voting Rights Act was Signed by President Lyndon B. Johnson. C.T. Vivian, a prominent figure in the Civil Rights Movement, was violently attacked by Sheriff Jim Clark while attempting to escort a group of African Americans to register to vote. Steve Fiffer is a New York Times Bestselling Author. His Book is "It's in The Action": Memories of a Nonviolent Warrior, Rev C.T. Vivian's Memoir.Reverend Vivian was a Major Force in the Fight for Civil Rights & Voters Rights in the Twentieth Century till he Passed July 17th, 2020.Regardless of Social Status, Party Affiliation or Belief, Race: Libertarian, Democrat, Progressive or Republican or Other, All Americans Should Have the Right to Vote!Senator Barack Obama, speaking at Selma's Brown Chapel on the March 2007, anniversary of the 1965 Selma to Montgomery marches, recognized Vivian in his opening remarks in the words of Martin L. King Jr. as "the greatest preacher to ever live."Studying for the ministry at American Baptist Theological Seminary (now called American Baptist College) in Nashville, Tennessee, in 1959, Vivian met James Lawson, who was teaching Mohandas Gandhi's nonviolent direct action strategy to the Nashville Student Movement. Soon Lawson's students, including Diane Nash, Bernard Lafayette, James Bevel, John Lewis and others from American Baptist, Fisk University and Tennessee State University, organized a systematic nonviolent sit-in campaign at local lunch counters.Vivian helped found the Nashville Christian Leadership Conference, and helped organize the first sit-ins in Nashville in 1960 and the first civil rights march in 1961. In 1961, Vivian participated in Freedom Rides. He worked alongside Martin Luther King Jr. as the national director of affiliates for the SCLC. During the summer following the Selma Voting Rights Movement, Vivian is perhaps best known for, Vivian challenged Sheriff Jim Clark on the steps of the courthouse in Selma, Alabama, in 1965 during a drive to promote Black people to register to vote."You can turn your back on me, but you cannot turn your back upon the idea of justice," Vivian said to Clark as reporters recorded the interaction. "You can turn your back now and you can keep the club in your hand, but you cannot beat down justice. And we will register to vote, because as citizens of these United States we have the right to do it."Vivian conceived and directed an educational program, Vision, and put 702 Alabama students in college with scholarships (this program later became Upward Bound). His 1970 Black Power and the American Myth was the first book on the Civil Rights Movement by a member of Martin Luther King's staff.On August 8, 2013, President Barack Obama named Vivian as a recipient of the Presidential Medal of Freedom.Steve's own Memoir is "Three Quarters, Two Dimes, and a Nickel". His work has appeared in Chicago Tribune. & Slate. He's also a Guggenheim Fellow© 2026 All Rights Reserved© 2026 Building Abundant Success!!Join Me on ~ iHeart Media @ https://tinyurl.com/iHeartBASSpot Me on Spotify: https://tinyurl.com/yxuy23baAmazon Music ~ https://tinyurl.com/AmzBASAudacy:  https://tinyurl.com/BASAud

Women's History, Episode #4 of 4. In the spring of 1966, inside a rented office space in New York City that smelled like cigarette smoke and mimeograph ink, a cadre of people worked for the Student Nonviolent Coordinating Committee (SNCC), pronounced “snick.” SNCC was one of many organizations, such as CORE, the SCLC, the NAACP, and others, working for the Civil Right Movement in the South. It had been a harrowing few years. 1964's Freedom Summer had been successful in rallying more Americans to support Civil Rights but also sparked extreme backlash that resulted in volunteers being beaten, harassed, and even killed. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In today's episode, we highlighted an OncLive Peer Exchange discussion about cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) moderated by Misty D. Shields, MD, PhD. Dr Shields is an assistant professor of clinical medicine in the Department of Medicine in the Division of Hematology/Oncology at the Indiana University (IU) School of Medicine, as well as an adjunct assistant professor of medical & molecular genetics and an associate member of Experimental and Developmental Therapeutics at the IU Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis. She was joined by Triparna Sen, MD, PhD, MS, a professor at The Ohio State University in Columbus, and Ditte Primdahl, MD, an assistant professor of neurology (neuro-oncology) and neurological surgery at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.In this exclusive conversation, the experts discussed the ties between cancer-associated LEMS and small cell lung cancer. They noted that LEMS is characterized by proximal muscle weakness, hyperreflexia, and autonomic dysfunction, and that diagnostic challenges include late referral to neurology and misattribution of symptoms to cancer-related fatigue. They also highlighted key symptoms, which include proximal leg weakness, dry mouth, and blurred vision. Furthermore, they dove into treatment options for symptom control and emphasized that a multidisciplinary approach to care, including oncology, neurology, and laboratory medicine, is crucial for early LEMS diagnosis and effective management.

In today's episode, we spoke with Joshua K. Sabari, MD. Dr Sabari is an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at NYU Langone Health's Perlmutter Cancer Center New York. In our exclusive interview, Dr Sabari discussed the complexities of managing small cell lung cancer (SCLC) across both academic and community settings, emphasizing that nothing about this disease is straightforward. He stressed the importance of rapid diagnosis and staging, ideally within 48 to 72 hours given how quickly patients can deteriorate, and noted that in his own academic practice, approximately 30% of patients never reach second-line therapy, a figure that climbs to 50% to 60% in the community setting.He highlighted 2 areas where community implementation frequently breaks down: first-line maintenance and second-line therapy. Regarding maintenance, Dr Sabari underscored the need to counsel patients about the combination of atezolizumab (Tecentriq) plus lurbinectedin (Zepzelca) from the outset of treatment, so the transition after 4 cycles of chemoimmunotherapy is not a surprise. In the second-line setting, he addressed the practical challenges of administering tarlatamab-dlle (Imdelltra), a CD3 x DLL3 bispecific T-cell engager, noting that the first 2 doses require inpatient monitoring given the risks of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). However, he noted that these monitoring resources may not be readily available outside of academic centers.The discussion also covered the evolving role of the multidisciplinary care team, with Dr Sabari highlighting the outsized impact of dedicated thoracic pharmacists in educating patients, monitoring for adverse effects (AEs), and intervening early, particularly with novel agents whose AE profiles are still being characterized. He shared real-world examples of coordination saves, including a radiologist who flagged early pneumonitis and a patient receiving tarlatamab who developed subtle cognitive changes that were initially missed.Finally, Dr Sabari outlined the top educational gaps for community teams: understanding the biological heterogeneity of SCLC, recognizing when and how to use emerging agents such as tarlatamab and obrixtamig (BI 764532), and developing fluency in managing novel toxicities including CRS, ICANs, and interstitial lung disease associated with antibody-drug conjugates.

In this second part of TOGA's Conversations in Lung Cancer Research two-episode series, A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital, leads a panel discussing the clinical implications of the March 1st broad Pharmaceutical Benefits Scheme (PBS) listing of ipilimumab and nivolumab in Australia. Joined by Prof Nick Pavlakis (Senior Staff Specialist at Royal North Shore Hospital, Professor of Medicine at the University of Sydney, former chair of TOGA), Dr. Sam Bowyer (Medical Oncologist at Sir Charles Gairdner Hospital and Clinical Researcher at Linear Clinical Research) and Dr. Lavinia Tan (Medical Oncologist at Peter MacCallum Cancer Centre), the conversation explores how this newly granted flexibility alters treatment paradigms across various thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, small cell lung cancer (SCLC), and rare thymic tumours while also addressing toxicity management and the growing demands of patient survivorship. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. (00:00) Welcome and Acknowledgement (01:33) Panel Introductions (02:52) First Reactions in Clinic (05:01) Frontline NSCLC Evidence (06:48) Who Gets Ipi Nivo? (11:29) Chemo Free and Rechallenge (15:20) Stopping or Continuing IO (20:34) Mesothelioma Treatment Choices (27:20) Small Cell Reality Check (30:21) Thymic Malignancies Debate (34:54) Governance and Toxicity Safety (38:44) Survivorship and Follow Up (43:43) Real World Data Next Steps (48:05) Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Radiation therapy is a powerful and non-invasive tool in the management of small cell lung cancer (SCLC), but radiation oncologists are not always fully integrated into the care team. In this episode, CANCER BUZZ speaks with Charles B. Simone, II, MD, FASTRO, FACRO, FACR, chief medical officer of the New York Proton Center and radiation oncologist at Memorial Sloan Kettering Cancer Center, about strategies to improve collaboration between radiation and medical oncology. He discusses some of the biggest barriers and greatest rewards of enhancing this partnership and expanding access to radiation therapy for SCLC. Guest: Charles B. Simone, II, MD, FASTRO, FACRO, FACR  Research Professor and Chief Medical Officer New York Proton Center Radiation Oncologist Memorial Sloan Kettering Cancer Center New York, NY "While we don't have large, randomized trials really telling us how the modalities should be sequenced, that really should be a discussion and personalized for each patient." —Charles B. Simone, II, MD, FASTRO, FACRO, FACR "After a slow 20 years of limited progress, this last half a decade has seen dramatic progress for small cell, and with that, the multidisciplinary collaboration is even more important." —Charles B. Simone, II, MD, FASTRO, FACRO, FACR Resources: Comprehensive Quality Care for Patients With Small Cell Lung Cancer Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer  

Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00) Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25) Considerations with maintenance therapy for ES-SCLC (9:31) Considerations with immunotherapy for ES-SCLC (13:12) Curability of SCLC with systemic therapy (15:17) Data with chemoimmunotherapy for patients with poor performance status (25:55) Future developments in therapy for SCLC (30:11) Rapid fire: Small Cell 101 (35:45) CME information and select publications  

Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics: Overview of small cell lung cancer (SCLC) (0:00) First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50) Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36) Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide followed by maintenance lurbinectedin/atezolizumab (18:46) Case: A woman in her mid 70s with ES-SCLC experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (21:21) CME information and select publications

Dr. Christine Lovly and Dr. Vamsi Velcheti discuss practice-changing lung cancer data presented at the 2026 ASCO Annual Meeting, including key studies on squamous cell lung cancer, NSCLC, and SCLC. LINK TO FULL TRANSCRIPT

In today's episode, we spoke with Jacob Sands, MD. Dr Sands is the associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Sands discussed the rapidly evolving treatment landscape for small cell lung cancer (SCLC), emphasizing both the progress made with immunotherapy and the ongoing challenges associated with this aggressive disease. He noted that outcomes now vary widely, with some patients experiencing long-term durable disease control following checkpoint inhibitor therapy, while others continue to have limited benefit from currently available treatments.A major focus of the discussion centered on tarlatamab-dlle (Imdelltra), the DLL3-targeting bispecific T-cell engager approved for relapsed SCLC. Sands described tarlatamab as a “new paradigm” therapy, highlighting results from the phase 3 DeLLphi-304 trial (NCT05740566) showing superiority in progression-free survival, overall survival, symptom improvement, and toxicity outcomes vs chemotherapy in the second-line setting. He also reviewed the evolution of DLL3 as a therapeutic target, explaining how earlier efforts with rovalpituzumab tesirine (Rova-T) helped establish the foundation for newer, more effective DLL3-directed approaches. The conversation also explored the growing role of molecular subtyping in SCLC, including emerging data involving ASCL1, NEUROD1, and POU2F3 transcription factor subsets. Although Sands cautioned that these findings remain investigational, he noted that subtype-driven treatment selection may eventually help personalize therapy in SCLC.Sands also addressed real-world experience with tarlatamab, including higher observed rates of cytokine release syndrome and neurologic toxicities among patients who would not have qualified for clinical trials. Despite these risks, he emphasized that many heavily pretreated patients with poor performance status or brain metastases have still achieved meaningful and durable clinical benefit.Finally, the discussion covered recent updates to National Comprehensive Cancer Network guidelines, including the establishment of tarlatamab as a preferred second-line standard of care regardless of chemotherapy-free interval. Looking ahead, Sands highlighted the growing pipeline of investigational therapies in SCLC, including CAR T-cell therapies, antibody-drug conjugates, radioligand therapies, and additional T-cell engagers, stressing the importance of clinical trial referral and collaboration between academic and community oncology centers.

Send us Fan MailTogetherness is not a warm slogan, it's the only way we meet the scale of what's in front of us. From the start, we press on a simple question: how do you remember the past honestly without letting it turn into bitterness? In this episode, Bishop Wright has a conversation with Senator Jon Ossoff about faith, leadership, and what it takes to build a better world when the headlines feel like a steady stream of bad news. Ossoff traces his moral education through the legacy of Congressman John Lewis and the civil rights movement in Georgia, including the historic alliance between Black and Jewish communities in the South. He shares the powerful symbolism of being sworn into the US Senate on scripture belonging to Rabbi Jacob Rothschild, the Atlanta rabbi whose temple was bombed in 1958 for supporting Dr. King and the SCLC. They discuss what interfaith coalition building looks like when it's real, not performative, and why serious faith traditions should pull us alongside each other when the stakes are high. Listen in for the full conversation. Born and raised in Georgia, Senator Jon Ossoff serves as our Senior United States Senator. Since his election, Sen. Ossoff has built bipartisanship in the Senate to achieve meaningful legislative results for Georgia — even in a divided Congress. In his first two years in office, Sen. Ossoff passed into law more standalone bills than any other freshman Senator. Sen. Ossoff's legislative achievements include laws to protect children online; to strengthen public safety; to tackle the opioid epidemic and prevent fentanyl trafficking across the Southern Border; to investigate unsolved lynchings and Civil Rights murders; to strengthen mental health care services for veterans; and to fight corruption and improve security in U.S. prisons. Mentored by civil rights legend Congressman John Lewis, Sen. Ossoff previously led a small business that produced investigative journalism exposing war crimes, public corruption, human trafficking, and organized crime. Sen. Ossoff lives with his wife, Dr. Alisha Kramer, and two daughters in Atlanta.Support the show Follow us on IG and FB at Bishop Rob Wright. 

Three years after her small cell lung cancer diagnosis, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, medical oncologist at Weill Cornell Medicine, to talk about the rapid changes transforming SCLC care. From immunotherapy and bispecific T-cell engagers to emerging targeted therapies, this episode unpacks what every patient should know about today's treatment landscape. You'll learn why clinical trials are NOT a last resort, why you should ask about them at your very first appointment, and how to advocate for yourself through side effects and treatment decisions. Dr. Saxena also explains the evolving role of biomarker testing in small cell lung cancer and shares why he's more hopeful than ever about patient outcomes. Whether you're newly diagnosed, a long-term survivor, or a caregiver, this conversation delivers honest answers and real hope. Guests: Dr. Ashish Saxena, Medical Oncologist, Weill Cornell Medicine Wendy Brooks, Patient Co-Host, Living with Small Cell Lung Cancer Show Notes: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-SCLC-Clinical-Trials-Long-Term-Outlook-Show-Notes.pdf  Transcript: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-SCLC-Clinical-Trials-Transcript.pdf  Video: https://youtu.be/RCwJvdcOS-4  For more information, visit lcfamerica.org.

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, to discuss the current treatment algorithms for small cell lung cancer (SCLC). Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ We dived deep into the aggressive nature of SCLC and the meaningful advances in treatment over the past few years. Key topics included: • The role of surgery and adjuvant chemotherapy in early-stage SCLC. • Insights into the ADRIATIC study, which highlighted the efficacy of Durvalumab in limited-stage disease. • The debate surrounding prophylactic cranial irradiation (PCI) and its implications for patient care. • The latest findings from the IMforte study, showcasing the combination of Atezolizumab and Lurbinectedin as a new standard of care in extensive-stage SCLC. • The promising results of Tarlatamab in the second-line setting and its impact on overall survival. Join us as we explored these advancements and their potential to improve patient outcomes in the fight against small cell lung cancer. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #SmallCellLungCancer, #SCLC, #ADRIATIC, , #IMforte, #OncologyBrothers

In today's episode, we spoke with Alissa Cooper, MD. Dr Cooper is a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Cooper discussed recent advances that have reshaped the treatment paradigm for small cell lung cancer (SCLC), particularly in the relapsed setting. She highlighted the FDA approval of tarlatamab-dlle (Imdelltra), a DLL3-targeting T-cell engager, as one of the most impactful developments in recent years. Despite this progress, Cooper emphasized that the frontline standard of care has remained largely unchanged, continuing to rely on platinum-based chemotherapy in combination with immunotherapy. She noted that, although ongoing clinical trials are exploring biomarker-driven strategies and novel combinations, a more personalized first-line approach has yet to be established.The conversation also explored real-world treatment sequencing and decision-making at the point of relapse. Cooper explained that, whenever feasible, oncologists aim to enroll patients in clinical trials or initiate treatment with tarlatamab. However, logistical barriers, including trial screening requirements and the need for monitored administration of T-cell engagers, can delay care. In cases of rapidly progressing disease, oncologists may instead turn to cytotoxic therapies such as lurbinectedin (Zepzelca) or use localized approaches like radiation to achieve faster disease control.The importance of multidisciplinary coordination was another key theme. Cooper underscored that SCLC management requires rapid collaboration among medical oncologists, radiation oncologists, pulmonologists, pathologists, and supportive care teams. Early involvement of palliative care is also critical, given the aggressive nature of the disease and high symptom burden.Additionally, she highlighted the essential role of oncology pharmacists, nursing teams, and structured patient education. Clear toxicity management protocols, dose-modification guidelines, and comprehensive patient education visits help ensure safe treatment delivery and empower patients to manage adverse effects.Looking ahead, Cooper described an “embarrassment of riches” in emerging therapies and targets under investigation. Beyond DLL3, novel approaches targeting markers such as SEZ6 and B7-H3, as well as next-generation antibody-drug conjugates and trispecific T-cell engagers, are showing early promise. However, key questions remain regarding biomarker selection, treatment sequencing, and real-world effectiveness, particularly for patients who would not meet clinical trial eligibility criteria.Finally, she emphasized that improving coordination between community and academic centers is essential to ensuring timely access to innovative therapies and clinical trials. Strengthening communication pathways and referral processes may help bridge gaps in care and improve outcomes for patients with this aggressive disease.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

In today's episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC). Dr Leal is a professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute in Atlanta, Georgia.In our exclusive interview, Dr Leal began by discussing how SCLC management can differ widely across community settings according to how patients present. Leal emphasized the importance of quickly confirming a patient's diagnosis and initiating treatment to avoid missing the critical window where chemotherapy could provide meaningful clinical benefit. However, Leal noted that the field still lacks predictive biomarkers to guide treatment selection. Accordingly, current strategies, including chemoimmunotherapy, maintenance approaches, and second-line options like tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca) are largely chosen based on clinical factors such as disease burden, comorbidities, and patient preferences.The conversation then shifted to the challenge of treating patients who may not meet traditional clinical trial eligibility criteria due to poor performance status, comorbidities, or social vulnerabilities. Leal stated that a multidisciplinary approach, including collaboration with supportive care teams, is essential to optimize outcomes for these patients. She noted that potential solutions to restrictive trial eligibility criteria may include decentralizing trials, improving collaboration between academic and community centers, and providing additional patient support such as transportation and care navigation services.Looking ahead, Leal emphasized the need for community practices to prepare for emerging therapies, including antibody-drug conjugates and novel immunotherapy approaches. Successfully integrating these treatments into everyday practice will require education, infrastructure development, and multidisciplinary collaboration, Leal imparted.

In today's episode, we spoke with Misty D. Shields, MD, PhD, about the realities of treating patients with small cell lung cancer (SCLC) in the community setting and how emerging therapies are shaping care delivery. Dr Shields is a translational medical oncologist at Indiana University Health in Indianapolis. In our exclusive interview, Dr Shields highlighted the urgency associated with SCLC treatment, an aggressive malignancy that often presents with rapid symptom onset and widespread metastases. The conversation also underscored the importance of multidisciplinary care. This approach is especially critical in light of expanded treatment options such as chemoimmunotherapy regimens, second-line therapies including tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca), along with clinical trials evaluating antibody-drug conjugates and radioligand therapies.From a practical standpoint, integrating these therapies into the community setting presents logistical challenges. Shields noted that although immunotherapy has been rapidly adopted since its introduction into standard care around 2019, newer agents require additional infrastructure. Education gaps remain another key issue. The growing availability of clinical trials and new treatment strategies makes it essential to guide patients through potential care pathways, helping them understand options across the first-line, maintenance, and relapsed settings.Looking ahead, molecular characterization may play a larger role in shaping treatment strategies. Ongoing research efforts, including cooperative group studies, aim to determine whether these subtypes can guide more personalized treatment approaches in the future. The discussion concluded with a call for continued infrastructure development in community oncology. 

Nat'l Media , Historic EventI am BOTH a Northerner & present Washingtonian who was born after the Historic Marches for My Civil Rights to Vote, Education, Public Accommodations,Transportation & EmploymentMajor Media Nationally & Internationally covered in the Marches. Citizens & Celebrities also participated:Joan Baez, James Baldwin, Harry Belafonte, Tony Bennett, Leonard Bernstein, Sammy Davis, Jr., Billy Eckstein, Dick Gregory, Lena Home, Mahalia Jackson, William Marshall, Johnny Mathis, Nina Simone, Susan Sarandon, Pernell Roberts, Peter,Paul & Mary....My Guest is the Reverend Clarence Varner who was in Grade School when he joined the Marches for Civil Rights in the 1960's. Although it cost Him is Part-Time Job while a Teenager, He held on to his Beliefs to Stay in the Fight, even getting Arrested Several times & Tear Gassed, Cattle Prod Shocked, Attack Dogs & Fire Hosed because he stood with others to Petition the the Governor for the Right for Blacks to Vote.Rev. Clarence Varner served  The United States in the Marine Corps for 8 years & served in during Vietnam during the War , he was wounded. Today he serves his God,  Country & Community in the continued fight for Civil Rights*In 1965, Blacks could not: *go to eat, Blacks were served at the Side or Back Door.*Social Movie Theatres, & Clubs too*Schools in the South & other State were Segregated*Housing was Segregated in Much of America. Redlining was the norm.* Thriving Middle Class Black Business's in Black Communities were forced out of Business due to the Federal Highway's that were built OVER that land.* Separate water Fountains & Bathrooms*Separate Transportation on Buses & Trains, etc.* Upper Corporate Jobs were not opened to most Blacks These Marches were ignited by the Death of SCLC local Jimmie Lee JacksonWhat did Jimmie Lee Jackson accomplish?Jimmie Lee Jackson, was a Vietnam veteran, Baptist deacon, activist and martyr of the Civil Rights Movement. Jackson, active in the fight for equal rights, had tried multiple times to register to vote in Alabama and was denied each time.When Jimmie Lee Jackson saw his frail 80-year-old grandfather rudely turned away from the registrar's office in 1962 after attempting to register to vote in Marion, Ala. He knew he had to join the civil rights movement.On Feb. 18, 1965, he was among more than 200 people participating in a night march in Marion. Before they had walked a block, they were confronted by state troopers and the police chief, who ordered them to disperse.Jackson and his mother huddled for safety in a café. When Jackson's grandfather entered the café bloodied and beaten, the young man tried to take him to a hospital. But they were quickly shoved back by a crowd of club-swinging troopers and terrified marchers. Another trooper pulled his pistol and shot Jackson in the stomach. It was two hours before Jackson arrived at the hospital in Selma. He died eight days later.At one of two services for Jackson, Dr. Martin Luther King Jr. told a crowd of 2,000: “Jimmie Lee Jackson's death says to us that we must work passionately and unrelentingly to make the American dream a reality. His death must prove that unmerited suffering does not go unredeemed.”© 2026 Building Abundant Success!!2026 All Rights ReservedJoin Me on ~ iHeart Media @ https://tinyurl.com/iHeartBASAmazon Music ~ https://tinyurl.com/AmzBASAudacy:  https://tinyurl.com/BASAud

Time Magazine, CNN, Media Images & Reporting Reflect the Colors of Change.This Week I Take Time to Reflect & Just Breathe. Also Reflect of Things Happening in Our World. In Remembrance of Jimmie Lee Jackson & The Late Honorable John Lewis (D,GA).In 2026, We are STILL Fighting the Good Fight for Voter's Rights for ALL.I have been Blessed to Meet, Learn, Train & Work along side of Several Civil Rights Icons. On of them was the Late The Honorable John Lewis (D,GA) who Fought & Marched in 2020 to the Very End!!I have attended events Remembering the History, People & Sacrifice.The Fight for Justice Continues Today in 2026 as People Help Bring About Change.My Guest this Week was asked to join the Selma March in Alabama in 1965 by Dr. Martin Luther King. His name: Joseph Cooney Esq., then a newly ordained Priest. He also worked with SCLC in the Voters Registration Summers of 1966-67.In 1965, State Troopers Clashed with Citizens marching to Montgomery, Alabama to petition the state for African-American's Right to Vote. Many lives would change in this fight. Some lives both Black & White lost. The March from Selma to Montgomery was inspired by the death of Jimmie Lee Jackson was a civil rights activist in Marion, Alabama, and a deacon in the Baptist church. On February 18, 1965, while participating in a peaceful voting rights march in his city, he was beaten by troopers and shot by Alabama State Trooper John Bonard Fowler Jackson was unarmed and died eight days later in the hospital.His death was part of the inspiration for the Selma to Montgomery marches in March 1965, a major events in the American Civil Rights Movement that helped gain Congressional passage of the Voting Rights Act of 1965. This opened the door to millions of African Americans being able to vote again in Alabama and across the South, regaining participation as citizens in the political system for the first time since the turn of the 20th century, when they were disenfranchised by state constitutions and discriminatory practices.© 2026 Building Abundant Success!!© 2026 All Rights Reserved Join Me on ~ iHeart Media @ https://tinyurl.com/iHeartBAS Spot Me on Spotify: https://tinyurl.com/yxuy23baAmazon ~ https://tinyurl.com/AmzBASAudacy:  https://tinyurl.com/BASAud

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics: Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00) Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13) Case: A woman in her early 60s newly diagnosed with ES-SCLC who receives first-line atezolizumab/EP and maintenance atezolizumab with delayed addition of lurbinectedin — Dr Borghaei (16:21) Case: A woman in her mid 60s with multiple comorbidities newly diagnosed with ES-SCLC who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin with discontinuation of lurbinectedin — Dr Borghaei (23:46) Clinician Survey Results (32:16) Case: A woman in her early 70s with multiple comorbidities and newly diagnosed ES-SCLC with TP53 and RB1 mutations who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin — Dr Chiang (41:39) Case: A man in his mid 70s with multiple comorbidities and a history of limited-stage SCLC managed with chemoradiation therapy who enrolls in the DeLLphi-312 trial upon disease recurrence — Dr Chiang (47:20) Promising Investigational Strategies — Dr Chiang (49:14) CME information and select publications

In today's episode, we spoke with Anne Chiang, MD, PhD, to discuss the rapidly evolving treatment landscape in small cell lung cancer (SCLC) and what this new era of innovation means for patients. Dr Chiang is an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine and associate cancer center director for clinical initiatives at Yale Cancer Center in New Haven, Connecticut.In our exclusive interview, Chiang reflected on how the field has shifted since the introduction of chemoimmunotherapy in 2018, highlighting improvements in median overall survival and the emergence of long-term responders in extensive-stage disease. Chiang also explored the growing understanding of disease heterogeneity, and the evolution of biomarker-informed strategies like under evaluation in the phase 2 S2409 PRISM trial (NCT06769126).Additionally, Chiang examined the clinical effect of DLL3-targeted therapies, including the recently approved bispecific antibody tarlatamab-dlle (Imdelltra), and how surface-targeting strategies are expanding options beyond traditional chemotherapy. Beyond efficacy, Chiang underscored the importance of individualized decision-making by assessing patient fitness beyond ECOG performance status, navigating treatment urgency in rapidly progressive disease, and balancing durability with toxicity when counseling patients on therapy.

Are you up to date on the management of extensive-stage small cell lung cancer (ES-SCLC)? Credit available for this activity expires: 2/20/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/quick-talk-es-sclc-what-community-clinicians-need-know-now-2026a100055m?ecd=bdc_podcast_libsyn_mscpedu

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Are you up to date with the latest management for extensive-stage small cell lung cancer? Credit available for this activity expires: 2/11/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/case-case-managing-es-sclc-real-world-through-patient-2026a10003ro?ecd=bdc_podcast_libsyn_mscpedu

In this podcast, experts Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; and Jacob M. Sands, MD; discuss immune checkpoint inhibitor–based strategies in limited-stage (LS) and extensive-stage (ES) small cell lung cancer (SCLC), practical considerations for integrating novel agents such as tarlatamab and lurbinectedin, and the emerging role of antibody-drug conjugates in the treatment of ES-SCLC.

This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease. Guests: Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer. Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.

Curtis Yarvin claims key civil rights institutions were shaped by former Communist Party operatives, pointing to Stanley Levison's role advising MLK and the SCLC. He argues American political narratives often hide uncomfortable realities, comparing media control, propaganda, and mythmaking across the 20th century.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

 Voters Right Act, Chicago Tribune, Slate, NY TimesAugust 6th, 1965 the Voting Rights Act was Signed by President Lyndon B. Johnson., C.T. Vivian, a prominent figure in the Civil Rights Movement, was violently attacked by Sheriff Jim Clark while attempting to escort a group of African Americans to register to vote. Steve Fiffer is a New York Times Bestselling Author. His Book is "It's in The Action": Memories of a Nonviolent Warrior, Rev C.T. Vivian's Memoir.Reverend Vivian was a Major Force in the Fight for Civil Rights & Voters Rights in the Twentieth Century till he Passed July 17th, 2020.Regardless of Social Status, Party Affiliation or Belief, Race: Libertarian, Democrat, Progressive or Republican or Other, All Americans Should Have the Right to Vote!Senator Barack Obama, speaking at Selma's Brown Chapel on the March 2007, anniversary of the 1965 Selma to Montgomery marches, recognized Vivian in his opening remarks in the words of Martin L. King Jr. as "the greatest preacher to ever live."Studying for the ministry at American Baptist Theological Seminary (now called American Baptist College) in Nashville, Tennessee, in 1959, Vivian met James Lawson, who was teaching Mohandas Gandhi's nonviolent direct action strategy to the Nashville Student Movement. Soon Lawson's students, including Diane Nash, Bernard Lafayette, James Bevel, John Lewis and others from American Baptist, Fisk University and Tennessee State University, organized a systematic nonviolent sit-in campaign at local lunch counters.Vivian helped found the Nashville Christian Leadership Conference, and helped organize the first sit-ins in Nashville in 1960 and the first civil rights march in 1961. In 1961, Vivian participated in Freedom Rides. He worked alongside Martin Luther King Jr. as the national director of affiliates for the SCLC. During the summer following the Selma Voting Rights Movement, Vivian is perhaps best known for, Vivian challenged Sheriff Jim Clark on the steps of the courthouse in Selma, Alabama, in 1965 during a drive to promote Black people to register to vote."You can turn your back on me, but you cannot turn your back upon the idea of justice," Vivian said to Clark as reporters recorded the interaction. "You can turn your back now and you can keep the club in your hand, but you cannot beat down justice. And we will register to vote, because as citizens of these United States we have the right to do it."Vivian conceived and directed an educational program, Vision, and put 702 Alabama students in college with scholarships (this program later became Upward Bound). His 1970 Black Power and the American Myth was the first book on the Civil Rights Movement by a member of Martin Luther King's staff.On August 8, 2013, President Barack Obama named Vivian as a recipient of the Presidential Medal of Freedom.Steve's own Memoir is "Three Quarters, Two Dimes, and a Nickel". His work has appeared in Chicago Tribune. & Slate. He's also a Guggenheim Fellow© 2026 All Rights Reserved© 2026 Building Abundant Success!!Join Me on ~ iHeart Media @ https://tinyurl.com/iHeartBASSpot Me on Spotify: https://tinyurl.com/yxuy23baAmazon Music ~ https://tinyurl.com/AmzBASAudacy:  https://tinyurl.com/BASAud

In today's episode I sit down with Frank, Kathie and Jonny Muse and talk with them about how they came to be the business they are today. Frank and Kathie have worked together for many years, and they wouldn't want it any other way. Building and growing a business for them has always been about family, treating their employees and customers right, and never being a single service outfit.We also talk about their involvement in the Sierra Cascade Logging Conference and how they've grown strong connections between industry and the community through their work with the SCLC. The annual Forest Products and Construction Equipment Expo will be held at the Shasta District Fair & Event Center in Anderson, California from Thursday February 5th to Saturday February 7th, 2026. The area will be filled with vendors from all sides of the industry, a log loading competition and an excavator rodeo. You won't want to miss this event.I would like to thank Frank, Kathie and Jonny for taking time out of their busy day to sit down and chat with me.

In today's episode, we had the pleasure of speaking with Jacob Sands, MD, and Shailee Shah, MD, about considerations for diagnosing and managing Lambert-Eaton myasthenic syndrome (LEMS), particularly in the context of small cell lung cancer (SCLC). Dr Sands is associate chief of the Lowe Center for Thoracic Oncology and the Oncology Medical Director of the International Patient Center at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts. Dr Shah is a clinical assistant professor of neurology (MS/neuroimmunology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.  In our exclusive interview, Drs Sands and Shah discussed LEMS symptom identification, the importance of paraneoplastic panels for assessing neurologic dysfunction in patients with SCLC, the need for specific autoantibody testing, and what guidelines currently note as best practices for the diagnosis of this disease.